Regulatory Perspective

Slides:

Advertisements

Similar presentations

FDA\ CDER\OPASS\OB ASA-Industry Workshop,Sept ,2000 Bethesda, MD Multi-Clinic and Multi-National Trials: A regulatory perspective Charles Anello.

Advertisements

Office of New Animal Drug Evaluation Laura L. Hungerford, DVM, MPH, PhD Senior Advisor, Science and Policy, ONADE Professor, University of Maryland School.

Marc Bailie DVM, PhD Director In Vivo Facility Michigan State University, Chief Development Officer Integrated Nonclinical Development Solutions (INDS)

Integrating Cardiovascular Endpoints into toxicology studies: Preliminary Results from An Industry Survey Simon Authier, DVM, MBA, PhD Director - Safety.

Safety and Extrapolation Steven Hirschfeld, MD PhD Office of Cellular, Tissue and Gene Therapy Center for Biologics Evaluation and Research FDA.

1 Pharmacology/Toxicology information to submit an IND for an anticancer drug.

Mitochondrial Manipulation Technologies: Preclinical Considerations

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development Critical Path.

The ICH E5 Question and Answer Document Status and Content Robert T. O’Neill, Ph.D. Director, Office of Biostatistics, CDER, FDA Presented at the 4th Kitasato-Harvard.

Development and Review Process of NDA, ANDA/AADA and OTC Dr. Basavaraj K. Nanjwade M. Pharm., Ph. D Associate Professor Department of Pharmaceutics KLE.

Stefan Franzén Introduction to clinical trials.

+ Drug Development and Review Process. + Objectives Learn the processes involved in drug discovery and development Define the phases involved in FDA drug.

Neonatal/Juvenile Animal Safety Studies Kenneth L. Hastings, Dr.P.H., D.A.B.T. Office of New Drugs, CDER.

Postmarketing Risk Assessment of Drug Products Division of Drug Risk Evaluation Office of Drug Safety Center for Drug Evaluation and Research.

Clinical Trials of Traditional Herbal Medicines In India Y.K.Gupta Professor & Head, Department of Pharmacology, All India Institute of Medical Sciences,

Food and Drug Administration Preclinical safety data for “first in human” (FIH) clinical trials in healthy volunteer subjects Oncology Drug Advisory Committee.

Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines / October |1 | Regulatory Requirement on Dossier of Medicinal.

CDER IND/NDA Reviews Guidance, The Common Technical Document and Good Review Practice John K. Leighton, Ph.D., DABT CDER/FDA.

Food Advisory Committee Meeting December 16 and 17, 2014 Questions to the Committee Suzanne C. Fitzpatrick, PhD, DABT Senior Advisory for Toxicology Center.

Justina A. Molzon, MS Pharm, JD

Cellular Products for Cardiac Diseases Dwaine Rieves, MD Center for Biologics Evaluation and Research FDA Perspective on:

Center for Drug Evaluation and Research August 2005 Electroretinography: The FDA’s Viewpoint Wiley A. Chambers, MD Deputy Director Division of Anti-Infective.

Peter K.S. Siegl, Ph.D. Siegl Pharma Consulting LLC SAFETY PHARMACOLOGY: Opportunities and Expectations 8 th Annual Safety Pharmacology.

1 Safety Pharmacology for Oncology Pharmaceuticals at CDER John K. Leighton Associate Director for Pharmacology CDER/OND/OODP.

DRUG DEVELOPMENT & REGULATIONS DR ARIF HASHMI. DRUG DEVELOPMENT Discovery and synthesis Preclinical development (chemical testing, biological testing,

Adding Safety Pharm Endopoints To General Tox Studies - II Michael J Engwall, DVM, PhD Principal Scientist Safety and Exploratory Pharmacology Toxicology.

Nonclinical Perspective on Initiating Phase 1 Studies for Small Molecular Weight Compounds John K. Leighton, PH.D., DABT Supervisory Pharmacologist Division.

Respiratory Safety Pharmacology Endpoints in Toxicology Simon Authier, DVM, MBA, PhD Director - Safety Pharmacology and Veterinary Science CIToxLAB North.

Impact of E9 Addendum to Industry

Cancer Centers In Clinical Trials Sandrine Marreaud Head of Medical Department.

Summary of Findings Improving the System of Reporting and Interpreting Unexpected Serious Adverse Events to Investigators Conducting Research Under an.

The New Drug Development Process (www. fda. gov/cder/handbook/develop

Clinical Pharmacology Subcommittee of the Advisory Committee for Pharmaceutical Science Meeting April Quantitative risk analysis using exposure-response.

History of Pediatric Labeling

1 Updates on Regulatory Requirements for Missing Data Ferran Torres, MD, PhD Hospital Clinic Barcelona Universitat Autònoma de Barcelona.

Consider Incorporating Respiratory Safety Pharmacology Measurements into Your Next Repeat Dose Toxicology Study September 14, 2012 Jeff Tepper, PhD, DABT.

Cardiovascular Health Research Unit, Seattle, WA IOM recommendations on drug safety: relevance for vaccines? Bruce M Psaty, MD, PhD.

1 Nonclinical Perspective on Initiating Phase 1 Studies for Biological Oncology Products Martin D. Green, Ph.D. Supervisory Pharmacologist DBOP/OODP/CDER.

1 Markham C. Luke, M.D., Ph.D. Dermatology Clinical Team Leader DDDDP, ODE V, CDER, FDA Combination Topical Products for the Treatment of Acne Vulgaris.

ITFG/IPAC Collaboration BA/BE Technical Team ITFG/IPAC TECHNICAL TEAM: BA/BE IN VITRO AND IN VIVO TESTS Presented by: Stephen Farr, PhD 26 April 2000 Rockville,

Comments on FDA Concept Paper Sidney N. Kahn, MD, PhD President Pharmacovigilance & Risk Management, Inc. Risk Assessment of Observational.

Nonclinical Perspective on Initiating Phase 1 Studies for Biological Oncology Products – Case Studies Anne M. Pilaro, Ph.D. DBOP/OODP/CDER Oncology Drugs.

1 Destination India: Contract Research in Pharmaceuticals & Healthcare S.P. Vasireddi, Ph.D Chairman, ACRO 26/03/2009.

Overview of the CPSC Directorate for Health Sciences * Mary Ann Danello, Ph.D. Associate Executive Director * The views expressed in this presentation.

Topic #1: EOP2A Meetings Please comment on the goals of the proposed EOP2A meeting and the impact that such meetings could have on optimizing dose selection.

Bussara Sukpanichnant, Human Subject Protection Office, USAMD-AFRIMS Unanticipated Problems 15 th FERCAP International Conference 24 Nov 15 Nagasaki, Japan.

TOPRA Annual Veterinary Symposium Introduction to the Case Study A presentation by Lesley Reeve, Module leader.

1 Promotion in Management and Research Tracks in Industry Magdalena Alonso-Galicia, PhD Cardiovascular Diseases Department Merck Research Laboratories.

for Human Pharmaceuticals Kyung-Chul Choi D.V.M., Ph.D.

Clinical Review Process for New Drug Development and Application

Patient Focused Drug Development An FDA Perspective

Biosimilar Biological Products

Regulatory– Terms & Definitions רגולציה - מונחים והגדרות

Pre-Investigational New Drug (pre-IND) Meeting with FDA

ICH-GCP Avinash Kondawar M. Pharm Lead CRA

Industry Perspective: Expanded Access Programs

FDA’s IDE Decisions and Communications

Balancing Regulation and Innovation: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.

Reasonable Assurance of Safety and Effectiveness: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division.

Introduction of New Technology: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.

Pharmacovigilance in clinical trials

Dennis J. Murphy, PhD, DABT Director - Safety Pharmacology US

Suzanne M. Sensabaugh, MS, MBA

Evaluation of immunogenicity Case presentations CEMDC-PharmaTrain, Module 8. Budapest, Hungary, 12-May-2017 Vid Stanulovic MD, PhD Clinical pharmacologist,

FDA Tox Working Group Which goals of the FDA Roadmap are most important to FDA stakeholders? Integration of predictive technologies Replacing animal tests.

Statement on Concerta and Methylphenidate for the June 30, 2005 Pediatric Advisory Committee The FDA has identified two possible safety concerns with.

Development Plans: Study Design and Dose Selection

Dose setting for a Phase I Clinical Study

Regulatory Perspective of the Use of EHRs in RCTs

VICH GL 54, Studies to evaluate the safety of residues of veterinary drugs in human food: General approach to establish an Acute Reference Dose (ARfD)

Presentation transcript:

Regulatory Perspective John Koerner, Ph.D. Senior Pharmacologist CDER, DCRP

Disclaimer The views expressed are those of the presenter and do not necessarily reflect those of the FDA 2

Objectives of SP Studies This (S7A) guideline was developed to help protect clinical trial participants and patients receiving marketed products from potential adverse effects of pharmaceuticals, while avoiding unnecessary use of animals and other resources. 3

ICH Guidances ICH S7A – Safety Pharmacology “Some safety pharmacology endpoints can be incorporated in the design of toxicology (studies) … “ ICH S6 – Biotechnology Products ICH S9 – Oncology Products 4

For First in Human Studies Capture relevant CV safety signals to prevent catastrophic, life-threatening AEs HR, BP and ECG 5

Reduce attrition throughout development Worthwhile goal A regulatory issue when a safety concern to clinical trial participants – say, negative contractility in a fragile patient population. 6

Stand-Alone CV Safety Pharm Study Conscious, telemeterized animals Typically cross-over design Experience with standard drugs Known (and predictable) sensitivity 7

CV Endpoints in Toxicology Studies Sensitivity compared to stand-alone study? i.e., what can the study capture, and is this good enough? How best to demonstrate this sensitivity? 8

Safety Pharmacology Recommendations SPS – Best Practices* HESI Cardiovascular Safety Committee ^ * Best Practice in the conduct of key nonclinical CV assessments…; Leishman, et.al. ^ Cardiovascular Function in nonclinical drug safety assessment…; Sarazan, et.al. 9

Thank you